Get to know our clinical trials

Ensayo clínico de fase III, aleatorizado, doble ciego, adaptativo, controlado con placebo/paclitaxel de AVB-S6-500 en combinación con paclitaxel en pacientes con cáncer de ovario resistente al platino y recurrente

THE PURPOSE OF THIS RESEARCH STUDY IS TO EVALUATE THE SAFETY AND EFFICACY OF AVB-S6-500 IN COMBINATION WITH PAC (PACLITAXEL) IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER.

Status
In recruitment
headquarters
Madrid

Technical Summary

  • PHASE III, RANDOMIZED, DOUBLE-BLIND, DOUBLE-BLIND, ADAPTIVE, PLACEBO/PACLITAXEL-CONTROLLED STUDY OF AVB-S6-500 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH PLATINUM-RESISTANT AND RECURRENT OVARIAN CANCER.
  • Code EudraCT: 2021-000293-28
  • Protocol number: AVB500-OC-004
  • Promoter: Aravive, Inc
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.